1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • November 2016
  • 608 pages
  • ID: 4697520
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

Summary

Lung cancer is currently the most common cancer in the world, and is the most common cause of death from cancer worldwide. Of the total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, resulting in a poor prognosis.

NSCLC market in the 8MM in 2015 was US$6.21B. Just over half of these sales, US$3.25B (52.4%), were generated in the US, with the 5EU representing the next largest region by sales, estimated at US$1.53B (24.5%). Japan and China contributed the smallest proportions of sales to the global NSCLC market, with 2015 sales of US$981M (15.8%) and US$445M (7.2%), respectively.

By the end of the forecast period in 2025, GlobalData projects NSCLC sales to rise to US$26.71B in the 8MM, at a moderate Compound Annual Growth Rate (CAGR) of 15.7%. In particular, GlobalData expects the China NSCLC market to grow most rapidly, increasing to US$4.3B (16.1% of global NSCLC shares) by 2025 at a robust CAGR of 25.4%.
As per Cai Xuan, Analyst, explains: “NSCLC space was largely dominated by generic chemotherapy and targeted therapies, which accounted for around 94% of the market, while immuno-oncology sales accounted for just 6%. In 2025, that trend will be reversed, with 65% of the total NSCLC market going to immuno-oncology therapies, and the remaining 35% being split between chemotherapy and targeted agents.”

The report “PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025” provides an overview of NSCLC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options. Additionally, this report provides comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and also detailed analysis of late-stage pipeline products and topline NSCLC drug market revenue from 2015–2025, annual cost of therapy (ACOT), and major product sales in 17 patient segments during the forecast period are included.

Companies mentioned in this report: Abbvie, Amgen, Ariad Pharmaceuticals, Astellas Pharma, AstraZeneca, Betta Pharmaceuticals, BeyondSpring Pharmaceuticals, Bioven Group, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Hanmi Pharmacuticals, Hutchison MediPharma, Immunomedics, Merck & Co., Merck KGaA, Merrimack Pharmaceuticals, Novartis, Ono Pharmaceutical, OSE Immunotherapeutics, Pfizer, Roche/Genentech, Xcovery Holding Company.

Highlights

Key Questions Answered

- Based on interviews with key opinion leaders (KOLs), GlobalData has identified the major unmet needs in the NSCLC marketplace. Will the leading pipeline agents fulfil these unmet needs during the forecast period (2015-2025)?
- What research and development (R&D) strategies will companies leverage to compete in the future NSCLC marketplace?
- Which pipeline products are poised to make a major clinical and commercial impact?
- What clinical and commercial factors are likely to influence NSCLC drug uptake in the 8MM?

Key Findings

- The increasing incorporation of premium-priced immune checkpoint inhibitor immunotherapies into the NSCLC treatment algorithm, particularly in the first-line setting, will be one major driver. Collectively, immunotherapies will reach $17.5B in sales by 2025, accounting for roughly 65% of total sales in the NSCLC market. Of the $17.5B total, Keytruda, Opdivo, and Tecentriq are projected to contribute $5.2B, $5.5B, and $2.8B, respectively.
- The increasing incidence of NSCLC in the 8MM will also drive growth. China, in particular, will see its NSCLC incident cases increase dramatically over the forecast period, at an Annual Growth Rate (AGR) of 4.7%. Overall, across the 8MM, the incidence of NSCLC is expected to increase at an AGR of 3.1% from 2015-2025. This increase, coupled with an anticipated increase in branded therapy prescriptions in China, will drive the growth of both the Chinese and global NSCLC markets over the forecast period.
- Patent expiration of several blockbuster drugs, including Tarceva and Alimta, and the uptake of generics will limit growth. GlobalData expects sales of the patented drug in the 8MM to decrease from $783M in 2015 to $18M by 2025. In addition, sales of Alimta will decrease from $2.1B in 2015 to $54M in 2025.
- An increasing emphasis on cost-consciousness is anticipated over the forecast period, which will limit premium pricing opportunities for developers of NSCLC pipeline agents. GlobalData expects this era of austerity and healthcare reform to make it increasingly more difficult for pharmaceutical companies to gain reimbursement approval for their new NSCLC therapies.

Scope

- Overview of NSCLC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
- Topline NSCLC drug market revenue from 2015-2025, annual cost of therapy (ACOT), and major product sales in 17 patient segments during the forecast period are included.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, opportunities, R&D strategies, and clinical trial mapping for the NSCLC market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global NSCLC market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global NSCLC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NSCLC market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
30% Off

($10995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Gliosarcoma - Pipeline Review, H2 2019

Gliosarcoma - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Gliosarcoma - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma - Pipeline Review, H2 2019, provides an overview of the Gliosarcoma (Oncology) pipeline ...

Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H2 2019

Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H2 2019SummaryTyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Tyrosine-protein kinase receptor UFO is an enzyme encoded ...

Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2020

Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2020

  • $ 2500
  • January 2020

Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2020Summaryclinical trial report, “Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2020" provides an overview of Small-Cell Lung Cance ...


ref:plp2016

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on